CTMX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 16, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

CytomX Therapeutics Reports Q3 2026 Financial Results and Provides Pipeline and Business Updates

Nov 5, 2026

8-K

CytomX Therapeutics Announces Q2 2026 Financial Results and Business Updates

Aug 6, 2026

8-K

CytomX Therapeutics Appoints Charles Fuchs, M.D., M.P.H. to Board of Directors

Jul 27, 2026

8-K

CytomX Therapeutics Announces Results of 2026 Annual Meeting and Approval of Equity Plan Amendments

Jun 22, 2026

8-K

CytomX Therapeutics and Regeneron Amend Collaboration Agreement to Expand Bispecific Cancer Therapy Programs

Jun 3, 2026

8-K

CytomX Therapeutics Announces Q1 2026 Financial Results and Business Update

May 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Mar 18, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $250,000,000 | Bank: Jefferies

Mar 16, 2026

424B5

REGISTERED OFFERING

May 12, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 25,961,539 | Warrants amount: 25,961,539 | Shares Purchased in June 2023 PIPE at $2.08

Aug 25, 2023

424B5

ATM | Offering amount: $63,296,000 | Amount sold to date: $11,704,000

Mar 4, 2022

424B5

Common Stock, Preferred Stock, Debt Securities,-

Jan 21, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2026

S-3ASR

March 2026 SHELF

Mar 16, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 7, 2025

S-3

August 2025 SHELF EFFECTIVE, DATED 2025-08-18

Aug 7, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 6, 2025

S-3

SHELF | ATM | Offering amount: $250,000,000.00 EFFECTIVE

Aug 9, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 20, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 1, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

BANK OF AMERICA CORP /DE/ (Filed by)

Oct 28, 2026

4/A

McCarthy Sean A. (Reporting)

Oct 16, 2026

SCHEDULE 13G/A

Point72 Asset Management, L.P. (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Kynam Capital Management, LP (Filed by)

Aug 14, 2026

SCHEDULE 13G

STATE STREET CORP (Filed by)

Aug 7, 2026

Carvajal Alejandra (Reporting)

Aug 5, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 19, 2025

CORRESP

Form CORRESP - Correspondence

Aug 14, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 13, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 20, 2024

CORRESP

Form CORRESP - Correspondence

Aug 15, 2024

LETTER

Form UPLOAD - SEC-generated letter

Aug 15, 2024

CytomX Therapeutics, Inc. CTMX · SEC Filings